Cannabinoid drug tested for aggression in disabled adults

NCT ID NCT05273320

Completed Symptom relief Sponsor: Hsiang-Yuan Lin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested the safety of nabilone, a synthetic cannabinoid, in 20 adults with intellectual and developmental disabilities who have severe aggression. The goal was to see if the drug is well-tolerated and to gather initial data on whether it might reduce aggressive behavior. Results will help design larger, more definitive studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nabilone (a synthetic cannabinoid similar to THC)
What this could lead to: If safe and effective, this could point toward a new treatment option for severe aggression in adults with intellectual and developmental disabilities.
What could go wrong: This is a very early, small Phase 1 trial with only 20 participants and no placebo group. It primarily tests safety, not effectiveness, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGGRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aggression developmental disability intellectual disability psychiatric disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSION BEHAVIOR PROBLEM DEVELOPMENTAL DISABILITY INTELLECTUAL DISABILITY

Contacts and locations

Show contact details

Locations

Centre for Addiction and Mental Health

Toronto, Ontario, M6J 1H4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.